Abstract
The use of PD-1 inhibitors has dramatically prolonged survival in patients with metastatic NSCLC. Quality of life was better compared to chemotherapy in prospective trials. However, the symptom trajectory over time is not well described, especially for patients who remain on treatment long term. Therefore, we sought to characterize the symptom burden longitudinally in a large population-based sample.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
